PRMT5 and neoplasm: To ensure safety, injections were administered every three days to allow for hematopoietic recovery between treatments, despite the main problem of PRMT5 inhibitors being hematological toxicity.[54] Reports suggest that combination therapy can modify intrinsic or extrinsic tumor factors, thereby enhancing the success rate of anticancer immunotherapy.[53, 55] Similarly, our study confirmed that PRMT5 promotes DNA damage repair through epigenetic modifications.